Research progress in proprotein convertase subtilisin/kexin type 9 monoclonal antibody

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in lipid regulation through interaction with low-density lipoprotein cholesterol receptors, and several types of PCSK9 inhibitors are gradually becoming research hotspots due to their lipid lowering effect. Among them PCSK9 monoclonal antibodies are the closest to clinical application, and a number of phase Ⅲ clinical trials in PCSK9 monoclonal antibodies have been completed in recent years. We systemically reviewed the current clinical research on PCSK9 monoclonal antibodies in this paper, in order to understand their efficacy and long-term safety in reducing the risk of cardiovascular diseases. Key words: Proprotein convertase subtilisin/kexin type 9; Monoclonal antibody; Dyslipidemia; Evolocumab; Alirocumab; Bococizumab